Drug Profile
Research programme: anxiety and depression therapeutics - ChemGenex
Alternative Names: CXS-301; CXS-302; CXS-303; CXS-304; CXS-305; CXS-307; CXS-308; CXS-309; CXS-310; CXS-311Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemGenex Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Australia
- 20 Jul 2007 Preclinical development is ongoing